Cardiff Oncology Inc
F:XE7C
Cardiff Oncology Inc
F:XE7C
Price:
1.351
EUR
-4.18%
Market Closed
Market Cap:
€60.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Cardiff Oncology Inc
F:XE7C
|
US |
|
S
|
SoftBank Group Corp
XMUN:SFT
|
JP |
|
M
|
Mondelez International Inc
F:KTF
|
US |
|
A
|
AT&T Inc
F:SOBA
|
US |
|
Stellantis NV
PAR:STLAP
|
NL |
|
I
|
Installed Building Products Inc
F:2IL
|
US |
|
U
|
United Utilities Group PLC
XMUN:UUEC
|
UK |
Wall St Price Targets
XE7C Price Targets Summary
Cardiff Oncology Inc
Cardiff Oncology Inc
Wall Street analysts forecast XE7C stock price to rise over the next 12 months.
According to Wall Street analysts, the average 1-year price target for XE7C is 7.382 EUR with a low forecast of 2.985 EUR and a high forecast of 10.639 EUR.
Lowest Forecast
Price Target
2.985
EUR
121% Upside
Average Forecast
Price Target
7.382
EUR
446% Upside
Highest Forecast
Price Target
10.639
EUR
687% Upside
Cardiff Oncology Inc Competitors:
Price Targets
Price Targets
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is XE7C's stock price target?
Price Target
7.382
EUR
7.382
EUR
According to Wall Street analysts, the average 1-year price target for XE7C is 7.382 EUR with a low forecast of 2.985 EUR and a high forecast of 10.639 EUR.
What is the Revenue forecast for Cardiff Oncology Inc?
Projected CAGR
166%
166%
Over the last 14 years, the compound annual growth rate for Revenue has been 6%. The projected CAGR for the next 8 years is 166%.
